1255860-32-2

Upstream product

• 1255860-31-1 1-[(2R,3R,4R,5R)-4-(benzyloxy)-5-(benzyloxy-methyl)-3-hydroxy-3-(2-hydroxyethyl)tetrahydrofuran-2-yl]pyrimidine-2,4(1H,3H)-dione 
• 885592-69-8 (2S,4R,5R)-4-(benzyloxy)-5-((benzyloxy)methyl)-2-methoxydihydrofuran-3(2H)-one 
• 1532523-61-7 C₂₆H₃₀N₂O₉S 
• 100-44-7 benzyl chloride 
• 80795-53-5 (2S,3R,4S,5R)-4-(benzyloxy)-5-((benzyloxy)methyl)-2-methoxytetrahydrofuran-3-ol 
• 64363-77-5 methyl 2,3,5-tri-O-benzyl-D-ribofuranoside 
• 1824-96-0 methyl ribofuranoside 

Downstream Products

• 1255860-34-4 (2S)-butyl-2-(((((4R,5R,7R,8R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-8-hydroxy-1,6-dioxa-spiro[3.4]octan-7-yl)-methoxy)(phenoxy)phosphoryl)amino)propanoate 
• 1375074-52-4 butyl N-[(R)-{[(4R,5R,7R,8R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-8-hydroxy-1,6-dioxaspiro[3.4]oct-7-yl]methoxy}(phenoxy)phosphoryl]-L-alaninate 
• 1255860-41-3 C₃₂H₃₂N₃O₁₀P 
• 1255860-38-8 methyl 2-((((4R,5R,7R,8R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-8-hydroxy-1,6-dioxaspiro[3.4]octan-7-yl)methoxy)(phenoxy)phosphorylamino)-2-methylpropanoate 
• 1255860-40-2 C₂₃H₃₀N₃O₁₀P 
• 1255860-39-9 C₃₁H₃₈N₃O₁₀P 
• 1255860-36-6 (2S)-benzyl-2-(((((4R,5R,7R,8R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-8-hydroxy-1,6-dioxaspiro[3.4]octan-7-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate 
• 1255860-37-7 (2S)-benzyl-2-(((((4R,5R,7R,8R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-8-hydroxy-1,6-dioxaspiro[3.4]octan-7-yl)methoxy)(phenoxy)phosphoryl)amino)butanoate 
• 1532523-80-0 C₂₇H₃₀N₃O₁₀P 
• 1532523-84-4 C₂₈H₃₂N₃O₁₀P 
• 1532523-83-3 C₂₈H₃₂N₃O₁₀P 
• 1532523-78-6 C₃₁H₃₂N₃O₁₀P 
• 1255860-35-5 C₂₅H₃₄N₃O₁₀P 
• 1532523-77-5 C₃₁H₃₂N₃O₁₀P 

Relevant academic research and scientific papers

SPIROCYCLIC NUCLEOSIDE ANALOGUES FOR THE TREATMENT OF HEPATITIS E

The present disclosure is directed toward spirocyclic nucleoside analogs, compositions comprising these compounds, and their use for treating hepatitis E infections.

Nucleotide prodrugs of 2′-deoxy-2′-spirooxetane ribonucleosides as novel inhibitors of the HCV NS5B polymerase

The limited efficacy, in particular against the genotype 1 virus, as well as the variety of side effects associated with the current therapy for hepatitis C virus (HCV) infection necessitates more efficacious drugs. We found that phosphoramidate prodrugs of 2′-deoxy-2′-spirooxetane ribonucleosides form a novel class of HCV NS5B RNA-dependent RNA polymerase inhibitors, displaying EC50 values ranging from 0.2 to >98 μM, measured in the Huh7-replicon cell line, with no apparent cytotoxicity (CC50 > 98.4 μM). Confirming recent findings, the 2′-spirooxetane moiety was identified as a novel structural motif in the field of anti-HCV nucleosides. A convenient synthesis was developed that enabled the synthesis of a broad set of nucleotide prodrugs with varying substitution patterns. Extensive formation of the triphosphate metabolite was observed in both rat and human hepatocyte cultures. In addition, after oral dosing of several phosphoramidate derivatives of compound 21 to rats, substantial hepatic levels of the active triphosphate metabolite were found.

SUBSTITUTED NUCLEOTIDE ANALOGS

Disclosed herein are phosphorothioate nucleotide analogs, methods of synthesizing phosphorothioate nucleotide analogs and methods of treating diseases and/or conditions such as viral infections, cancer, and/or parasitic diseases with the phosphorothioate nucleotide analogs.

Uracyl Spirooxetane Nucleoside Phosphoramidates

This invention relates to a stereochemically pure uracyl spirooxetane nucleoside phosphoramidate which inhibits the hepatitis C virus (HCV).

Uracyl Spirooxetane Nucleoside Phosphoramidates

This invention relates to a stereochemically pure uracyl spirooxetane nucleoside phosphoramidate useful in the treatment of patients infected with the hepatitis C virus (HCV).

URACYL SPIROOXETANE NUCLEOSIDE PHOSPHORAMIDATES

This invention relates to a stereochemically pure uracyl spirooxetane nucleoside phosphoramidate useful in the treatment of patients infected with the hepatitis C virus (HCV).

URACYL SPIROOXETANE NUCLEOSIDE PHOSPHORAMIDATES

This invention relates to a stereochemically pure uracyl spirooxetane nucleoside phosphoramidate of formula (I) which inhibits the hepatitis C virus (HCV).

URACYL SPIROOXETANE NUCLEOSIDES

Compounds of the formula (I) including any possible stereoisomers thereof, wherein: R4 is a monophosphate, diphosphate or triphosphate ester; or R4 is formula (II) or formula (III), R7 is optionally substituted phenyl, opt